Is Mettler-Toledo Stock Underperforming the Nasdaq?
/Mettler-Toledo%20International%2C%20Inc_%20phone%20and%20website-by%20T_Schneider%20via%20Shutterstock.jpg)
With a market cap of $24 billion, Mettler-Toledo International Inc. (MTD) manufactures and supplies precision instruments and services in the Americas, Europe, and internationally. Based in Columbus, Ohio, the company operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other Operations.
Companies worth $10 billion or more are typically referred to as "large-cap stocks." MTD fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the Diagnostics & Research industry. The company benefits from being the world's largest manufacturer and marketer of weighing instruments for use in laboratory, industrial, and food retailing applications.
However, the stock has retreated 25.3% from its 52-week high of $1,546.93 touched on Aug. 1, 2024. Shares of MTD have declined 3.9% over the past three months, underperforming the broader Nasdaq Composite’s ($NASX) 12.2% rise over the same time frame.
Shares of MTD have declined 21.6% over the past 52 weeks, underperforming $NASX’s 9.8% returns over the same time frame. Moreover, MTD stock is down 5.6% on a YTD basis, underperforming $NASX’s marginal uptick.
Shares of MTD have been trading below its 200-day moving average since February and above its 50-day moving average since early May.
On May 1, MTD stock declined 1.3% following the release of its Q1 earnings. The company posted revenue of $883.7 million in the period, which topped Street forecasts. Moreover, its adjusted EPS came in at $8.19, surpassing the consensus estimates by 3.7%. For the current quarter ending in June, Mettler-Toledo expects its per-share earnings to range from $9.45 to $9.70.
Its rival, IQVIA Holdings Inc. (IQV), has declined 20.2% in 2025 and 26.7% over the past year, underperforming the stock.
Analysts remain moderately optimistic about its prospects. The stock has a consensus rating of “Moderate Buy” from the 11 analysts covering it, and the mean price target of $1,290.40 implies a premium of 11.7% from the current market prices.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.